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The Effects of Autogenic-Feedback Training on Motion Sickness Severity and
Heart Rate Variability in Astronauts
WILLIAM B. TOSCANO* AND PATRICIA S. COWINGS
Antes Research Center
Summary
Space motion sickness affects 50 percent of all people
during early days of spaceflight. The present study
describes preliminary results of a Shuttle flight experi-
ment in which Autogenic-Feedback Training (AFT) was
tested as an alternative to pharmacological management
of this disorder. AFT is a physiological conditioning
method which has been used to train people to voluntarily
control several of their own physiological responses and
thereby suppress motion sickness symptoms. Thirteen
subjects participated in this study (tbur women and nine
men) of whom six later flew aboard the Space Shuttle. Of
the 13 subjects, 10 were given AFT. Of the six who were
designated as flight subjects, three were given treatment
and three served as control subjects (i.e., did not receive
AFT). All subjects participated in baseline data collection
sessions. These included both rotating chair and vertical
motion sickness inducing tests, and 12 hour mission
simulations. Treatment subjects were given rotating chair
motion sickness tests after 2, 4, and 6 hours of AFT.
Preflight results showed that AFT produced a significant
increase in tolerance to rotating chair motion sickness
tests. Further, this increased tolerance was associated with
changes in specific physiological responses and reports of
reduced malaise. Spectral analyses of heart rate variability
revealed that power in the low-frequency band decreased
after AFT, while power in the mid-frequency band
increased. Further, coherence between heart rate and
respiration was significantly higher after training.
The flight results showed that two of the three control
subjects experienced multiple vomiting episodes on the
first mission day, while one control subject experienced
only moderate malaise. All control subjects took
medication for symptom suppression and/or sedation. Of
the three treatment subjects, one experienced only mild
*Neuropsychiatric Institute, University of California at
Los Angeles, Los Angeles, California.
This work was funded in part by a Cooperative Agreement
(NCC2-115) between NASA Ames Research Center and the
University of California at San Francisco.
discomfort, one experienced moderate discomfort (one
vomiting episode on mission day 2), and one cxpericnccd
severe motion sickness on the first day. The lattcr subjcct
took a laxative on mission day 4 for symptoms unrclatcd
to motion sickness. None of the other treatment subjccts
took any medication throughout the flight. Mcasures of
cardiac function reflective of vagal control were shown to
be affected especially strongly on the first day of space-
flight. AFT given for control of heart rate, respiration, and
other autonomic activity influenced both the vagal control
measures and the space motion sickness symptoms
experienced. Comparisons of flight to ground-based
simulation data revealed significant difl'erences between
physiological responses on Earth and in space.
These data suggest that AFT may be an effectivc
treatment for space motion sickness, hut this is not
demonstrated conclusively with the small number of
subjects described in this paper. It was concluded that
continuous physiological monitoring combined with sell'-
reports of symptoms providcs an objective mcthod for
examining individual differences in adaptation to
spaceflight and the time course of this adaptation. Further,
it was possible to clinically predict from the preflight
training performancc which of the flight trcatmcnt
subjects would be most resistant and least resistant to
symptoms in space.
Introduction
The Problem of Space Motion Sickness
Since the Space Shuttle accidcnt in 1986 the Unitcd
States space program has undergone an extensive restruc-
turing. Additionally, the Unitcd States has renewed its
commitment to an American presence in space. This
commitment is evident by the eagerness of NASA, the
military, and private industry to return to spacc. All three
groups are planning manned missions into space. These
new plans include extended duration Shuttle missions
(30 days), the Space Station, a mission back to the moon,
and a mission to Mars.
Inspace,theabsenceofgravityalonecausesunique
physiologicalstress.Significantbiomedicalproblems
suchaslossofbodyfluids,diminishedmusculoskeletal
strength,cardiovasculardeconditioning,andreduced
sensorimotorcontrolhavebeenreported(Sandierand
Vernikos,1986).Thetimecourseofdevelopmentof hese
disordersandtheseverityofsymptomsexperiencedby
individualsvarywidely.A majorbiomedicalconcern
whichoccursearlyinthemissionisaformofmotion
sicknessknownasspacemotionsickness(SMS).
Motionsicknessi agenerictermwhichincludessea
sickness,airsickness,carsickness,simulatorsickness,
cineramasickness,pacesickness,etc.Eachconditionis
aformofthemaladyandisnamedaftertheenvironment
orvehicle.Generally,motionsicknessi inducedby
actualmotion;however,motionsicknesscanalsobe
inducedbyperceivedmotion.Althoughmotionsickness
canbeconsideredtobeadiseaseit isalsoanormal
responsetoanabnormalenvironment.Infact,theabsence
ofsymptomsduringamotionstimulusmayindicatea
deficientvestibularsystem(Dhenin,1978;Reasonand
Brand,1975).
Motionsicknessi aphysiologicaldysfunctioni duced
byarealorperceivedmotionstimulusandcharacterized
primarilybynausea,pallor,coldsweating,andvomiting(Dhenin,1978;ReasonandBrand, 1975; Homick,
Reschke, and Vanderploeg, 1984). Other possible
symptoms include salivation, feeling of warmth, light-
headedness, depression or apathy, yawning and drowsi-
ness, headache, and occasionally hyperventilation.
The currently accepted explanation for motion sickness is
the sensory conflict theory (Dhenin, 1978; Reason and
Brand, 1975). The theory suggests that the brain is
constantly receiving information from the visual system
and from the vestibular system on the position and
movement of the body. Sensors in muscles of the neck,
arms, legs, and other parts of the body also provide the
brain with positioning data known as proprioceptive
information. Motion sickness can occur when the brain
perceives these various signals to be in conflict with
normal motion cues (Gillingham and Wolfe, 1985).
Space motion sickness (SMS) is "characterized by
increased sensitivity to motion and head movements,
headache, malaise, lethargy, stomach awareness, loss of
appetite, nausea, and episodic vomiting" (Jenning, Davis,
and Santy, 1988). However, unlike terrestrial motion
sickness, space motion sickness rarely induces pallor or
sweat (Rcschke, 1990). In 1983, Graybiel and Lackner
studied the effect of motion sickness in microgravity and
macr_gravtty. Their data suggest that SMS is a result of
the brain receiving conflicting inlbrmation from the
visu_d system and the gravity receptors (otolilhs) of the
vestibular system. However, their data also point out that
motion sickness is enhanced when the eyes are opened
and the sight of the surroundings is permitted (Graybiel
and Lackner, 1983). These results agree with the actual
occurrences of space motion sickness during both
American and Russian spaceflight missions. Data from
these missions suggest that space motion sickness occurs
more frequently when astronauts and cosmonauts have
increased movement capability, greater exterior vision
and/or fewer internal visual orientation cues to rely on
(Homick, Reschke, and Vanderploeg, 1984).
Approximately 50 percent of all astronauts and
cosmonauts have suffered symptoms of SMS, ranging
from mild discomfort to repeated vomiting. There are
currently no ground-based methods for predicting
susceptibility to motion sickness in space. Data from
previous spaceflights indicate that some individuals who
have had wide exposure to motion devices and accelera-
tory forces on Earth or in aircraft, and who have never
previously shown any tendency to develop motion
sickness symptoms, were severely debilitated in space
(Bungo, Bagian, Bowman, and Levitan, 1987). Converse-
ly, some individuals who had a history of susceptibility to
motion sickness on Earth were unaffected by symptoms
in space. The earliest reported episode began within only
7 minutes of orbital insertion, and malaise has been
reported to last from I to 5 days. Finding a solution to this
biomedical problem has become a high-priority goal of
NASA because of its potential impact on crew safety,
comfort, and operational efficiency. Planned crew
activities are disrupted when space motion sickness
threatens crew safety, crew operations, and crew comfort.
To date, SMS has not claimed the lives of any astronauts,
but it has affected crew operations since the Apollo
missions (Homick, and Miller, 1975; Homick, Reschke,
and Vanderploeg, 1984).
Space motion sickness is a potential danger to susceptible
astronauts. Astronauts suffering from symptoms are
prohibited from performing extravehicular activities
(EVAs). An EVA is a very complex and dangerous
activity that requires 100 percent of the astronaut's mental
and physical abilities. A degradation in health, such as
headaches, malaise, or nausea, increases the danger of an
already dangerous situation. Further, astronauts would
probably asphyxiate from their own vomit if emesis
occurred in their space suits. Even crewmembers suffer-
ing from mild symptoms could be in danger during an
EVA because emesis can occur suddenly and without any
warning (Homick, Reschke, and Vandcrploeg, 1984).
NASA flight planners postponed planned EVAs for both
Apollo 9 and STS-5 Shuttle missions because crew-
members were suffering from space motion sickness
(Homick, Reschke, and Vanderploeg, 1984). Flight
controllerscanrescheduleorcancelplannedEVAsif
astronautsbecomesick;however,thereisnocontingency
plantocoveramissionscenarionwhichacontingency
EVAforeithertheorbiterorpayloadmustbepcrlbrmed
andthecrewissymptomatic.
Spacemotionsicknessi anoperationallyrelevant
biomedicalproblemforcrewedspaceflight.Davisandhis
colleagues(Davis,Vanderpleog,etal.,1988)reported
that71percentofthecrewmembersofthefirst24Space
Shuttlemissionsreportedsymptomsofspacesickness,
whichincluded26mildcases(30percent),20moderatc
(24percent),and11severe(I 3percent).Accordingtothe
NASAspacemotionsicknessgradingcriteria(tableI),
almosthalfofthe71percentofspacesicknesscases
impactedoperations.Also,accordingtothesymptom
gradingcriteria,evenamildcaseofspacemotionsick-
nessmayproduceretchingorvomiting,andsymptoms
maylastaslongas48hours.It isclearthatsucha
disordercouldpotentiallyjeopardizethesuccessof future
NASAandDODmissions.
TableI. Symptomgradingcriteriausedinspace
None
Mild
Moderate
Severe
Nosignsorsymptomsreportedwith
exceptionofmildtransientheadacheor
milddecreasedappetite.
Onetoseveralsymptomsofamild
nature;maybetransientandbrought
ononlyastheresultofheadmove-
ments;nooperationalimpact;may
includeasinglepisodeofretchingor
Vomiting;allsymptomsresolvedin
36to48hours.
Severalsymptomsofarelatively
persistentaturewhichwaxandwane;
lossofappetite;generalmalaise,
lethargy,andepigastricdiscomfort
maybethemostdominantsymptoms;
includesnomorethantwovomiting
episodes;minimaloperationalimpact;
allsymptomsresolvedwithin72hours.
Severalsymptomsofarelatively
persistentaturethatmaywaxand
wane;inadditiontolossofappetite
andstomachdiscomfort,malaise
and/orlethargyarepronounced;strong
desirenottomovehead;includesmore
thantwoepisodesofvomiting;signifi-
cantperformanced crementmaybe
apparent;symptomsmaypersist
beyond72hours.
ThcoperationalproblemI_scdbySMSisofsignificance
duringtheinitialphasesoflongdurationmissions,and
particularlyduringthecritical,shortduration(2-7days),
high-activitymissionsplannedfortheShuttle.Because
thesymptomsarepresentfrequentlyenoughinthefirst
fcwdaysofflightthercisasignificantconstraintonthe
levelofroutineactivitiesthatcanbcaccomplishedand,
therefore,planneduringthatime.Theimpactofspace
sicknessoncrewefficiencyhasledtothedevelopmentof
severaldifferentapproachesattemptingtopreventand
controlthismalady.Currently,therearetwotreatments
forspacemotionsickness:pharmocologicalagents(e.g.,scopolamineandpromethazine)andbehavioral
techniques(e.g.,autogcnicfeedbacktrainingand
biofeedback).
Pharmacological and Behavioral Countermeasures
Current NASA policy recommcnds treatment of
crcwmembers with moderate to severe symptoms of
SMS with intramuscular (IM) promcthazine 25-50 mg
(Davis, Jennings, Bcck, and Bagian, 1993). To rcduce the
possibility of drowsiness, this medication is given in the
presleep period on flight day 1. If symptoms develop
earlier than presleep and require treatment, IM prometh-
azine can be given and oral dextroamphetamine can be
added, to counter the effects of sedation (Schroedcr,
Collins, and Elam, 1985).
Observations that intramuscular injections of prometh-
azine are effectivc in attenuating motion sickness have
been evaluated during both ground-based and space
studies. Intramuscular promethazinc was first used during
a Shuttle flight in March 1989 and has been used on
14 other occasions sincc (Davis, Jennings, Bcck, and
Bajian, 1993). Intramuscular promethazine and its
efficacy in the treatment of spacc motion sickness wcrc
evaluated using standardized questions administered
during postflight debriefings. Results showed that
25 percent of crewmembers treated with IM promcthazinc
were "sick" on flight day 2, compared to 50 percent of
crcwmembers who did not rcceivc promcthazinc (Davis,
Jennings, Beck, and Bagian, 1993). in addition, symptom
relief occurred within 1-2 hours in 90 percent of
individuals treated with promethazine.
The efficacy of promethazine was also cvaluated on
subjects during zero gravity maneuvcrs in a KC- 135
aircraft. Subjects were given a 50 mg dose of promcth-
azine only if they experienced severe nausea or vomiting
and requested an injection. Within 10 minutes of IM
injection, 78 percent of individuals experienced symptom
relief, whereas 25 mg of promethazine was not effective
(Graybicl and Lackncr, 1987). Intramuscular injections
(25 mg) of promethazine increased motion sickness
toleranceby78percentduringcross-coupledangular
accelerations;injectionsweregiven30minutespriorto
testing(Wood,Stewart,Wood,andMims,1992).
Intramuscularinjectionsofpromethazinegiventoeight
subjects2hourspriortotestingintheslowrotationroom
alsoresultedinbeneficialeffects(Graybiel,Wood,etal.,
1975).
ThePhysician'sDeskReferenceautions,under
InformationforPatients,that"... promethazinemay
impairthementaland/orphysicalbilitiesrequiredforthe
pcrformanceofpotentiallyhazardoustasksuchas
drivingavehicleoroperatingmachinery"(Physician's
DeskReference,1993).Ground-basedstudieshave
shownthatsignificantdecrementsinpertbrmancescores,
psychomotorfunction,informationprocessing,and
alertnessmayoccurwithbothoralandIM injectionsof
promethazine.Foranoraldoseofpromethazine(12.5mg,
25rag),maximaleffectsmaybeseenoninformation
processingandpsychomotorperformance(t stedat
2hourintervals),3-4hoursalteringestion,withareturn
tobaselineafter8-9hours(ParrotandWesnes,1987).
Impairedynamictrackingperformanceandreduced
abilitytomaintainvisualfixationwereobservedfollow-
ingoralingestionof25mgofpromethazine(Wood,
Manno,etal.,1985).Decrementsinacomputerized
pursuitmotortaskIollowingbothoralandIM25mg
promcthazinew resignificant.Measurementsweremade
2,3,and4.5hourslollowingadministrationofmedica-
tions(Wood,Manno,etal.,1984).
Severalstudiesdemonstratemaximalimpairments5and
6hoursafterdrugadministration,whileperformance
remainedbelowbaseline!.5and7hourspostdrugoral
(10rag)(ClarkeandNicholson,1978).Large,Wayte,and
Turner(I971) notednodecrementsinhand--eyecoordina-
tion1.5hourspostdrug(25rag),withmaximalimpair-
mentat3hourspostdrug,followingoraladministration.
A similartimecoursefor50mgoraldosealsohasbeen
foundIorhand-eyecoordination(Molson,Mackay,
Smart,andTurner,1966).Flightsimulatorperformance
ofsubjectson25mgIMpromethazinedecreasedas
comparedtoperli_rmanceofsubjectsonplacebo(Taylor,
Dellinger,Hyman,andRichardson,1984).Decrementsin
trackingperformancew refoundI, 2,and4hours
followingadministrationfIM25and50mgprometh-
azineI'Schroeder,Collins,andElam,1985).Tracking
decrementsunaybeattributedtoreducedoptokinetic
nystagmuswhichmakeslessaccuratehefollowing
abilityof theeye(Collins,Schroeder,andElam,1982).
Impairment¢_finlbrmationprocessing,memory,reaction
lime,and' palial processing following IM injection have
not been assessed.
Motion sickness research has primarily focused on the
study of vestibular physiology, perceptual phenomena, or
pharmacological interventions in man and animals
(Reason and Brand, 1975). In contrast, Cowings and her
colleagues at Ames Research Center are using psycho-
physiological methods for studying motion sickness and
are developing a treatment for training people to control
their own motion sickness symptoms (Blizzard, Cowings,
and Miller, 1975; Cowings, 1990; Cowings, Billingham,
and Toscano, 1977; Cowings and Toscano, 1977, 1982;
Cowings, Toscano, et al., 1988; Cowings, Toscano,
Sekiguchi, and Ishii, 1993; Toscano and Cowings, 1982).
The method of treatment is Autogenic-Feedback Training
(AFT), a combination of biofeedback and Autogenic
Therapy (Schultz and Luthe, 1969), which involves
training physiological self-regulation as an alternative to
pharmacological management. The rationale for using
AFT to treat motion sickness was based on the observa-
tion that there were profound autonomic nervous system
(ANS) changes associated with this disorder (Cowings,
Suter, et al., 1986), and, although these responses are
highly idiosyncratic, they are repeatable over time
(Cowings, Naifeh, and Toscano, 1990; Stout, Toscano,
and Cowings, 1993).
Because certain ANS responses were correlated with, and
indeed predictors of (i.e., consistently preceded), reports
of motion sickness distress, it was hypothesized that
training subjects to control these responses might prevent
or reduce symptoms. The observed individual differences
in responding suggested that, to be effective, such training
would have to be directed at the different ANS responses
ibr different people. In other words, training would have
to be tailored for each individual.
AFT is a combination of several physiological and
perceptual training techniques, principal among these
are Autogenic Therapy (Schultz and Luthe, 1969) and
biofeedback (Miller, 1969). These two techniques have
been used widely to facilitate self-regulation of invol-
untary autonomic responses and minimize the debilitating
effects of various stressors. Biofeedback consists of
providing the subject with augmented sensory informa-
tion about the ongoing activity levels of some physio-
logical response (e.g., heart rate on a digital panel meter),
and rewarding him whenever such levels fluctuate in a
direction selected by the trainer (whenever heart rate
fluctuates above baseline). The result is an enhanced
ability by the subject to maintain the changed level for
increasing periods of time. Only repetition and practice
are required before physiological control is achieved.
Autogenic Therapy is an alternative sell-regulatory
technique that has been shown to have wide effects on
autonomic reactivity (Schultz and Luthe, 1969). This
trainingmethodinvolvestheuseofself-suggestion
exercisesthataredesignedtoinducebodilysensations
(e.g.,warmthinthehands)thatarehighlycorrelatedwith
specificphysiologicalresponsessuchasperipheral
vasodilatation(Harano,Ogawa,ndNaruse,1973).When
thesexercisesarepracticedinseries,theresultisa
relaxed(i.e.,parasympathetic-like)physiologicalprofile
withinthesubjectwhichpreventsheemergenceof
behavioralndphysiologicalreactionstostress.Cowings
(Blizzard,Cowings,andMiller,1975;Cowingsand
Toscano,1977)foundthathecombinedtechniques,
AFT,produceslargermagnitudephysiologicalchanges
thataremorereliableovertime.
Ground Studies of Motion Sickness
Money (1970), in his review of motion sickness research,
discussed many possible ANS changes during motion
sickness, but correctly noted that there was little consis-
tency in either procedures used or results of the available
research. The relative importance of autonomic nervous
system (ANS) responses in understanding and treating
motion sickness has been a matter of some controversy
(Graybiel, and Lackner, 1980). In a recent paper,
Cowings and colleagues (Cowings, Suter, et al., 1986)
examined the data of 127 people, all given the same
motion sickness test in order to describe the general trend
of ANS responses in all subjects. Individual differences in
initial motion sickness susceptibility were also examined
as a possible source of variability in ANS responding
reported by others (Parker, 1974; Parker and Wilsoncroft,
1978). Results clearly showed sympathetic-like activation
of four ANS responses during motion sickness stimula-
tion. These included significant changes in heart rate
acceleration, peripheral vasoconstriction, and increases in
skin conductance. Physiological response levels changed
rapidly and dramatically at the onset of stimulation and
when the test concluded. ANS response differences were
also found among motion sickness susceptibility groups,
with highly susceptible subjects producing, in general,
larger magnitude changes than the moderate or low
susceptible subjects.
In another study, comparisons were made of two separate
motion sickness tests on each of 58 subjects (Cowings,
Naifeh, and Toscano, 1990). Again, the same four
physiological responses (heart rate, finger pulse volume,
respiration rate, and skin resistance) were measured
during both motion tests. The objective of this study was
to examine individual differences in physiological
responding (i.e., response patterns) to motion stimuli and
determine how these data were related to self-reports of
motion sickness malaise experienced.
The results revealed eleven separate patterns of physio-
logical responding in which all or some combination of
the four physiological nneasures clearly reflected motion
sickness malaise levels of each of the 58 subjects.
Individual response patterns prc_luced on the first tests
were not significantly different than those of the second
test. Analyses showed thai of the 58 subjects, 27 showed
the same response patterns on both tests for all lout
physiological measures, 14 were stable for three vari-
ables, 6 were stable tor two, and I I were stable
responders for at least one variable.
Cowings (1990) reviewed a number of studies conducted
by her research group that examined AFT as a treatment
for motion sickness. In one study, differences in motion
sickness tolerance were compared in subjects given AFT,
an alternative cognitive task (computer Blackjack), or no
treatment (Toscano and Cowings, 1982). Two hours of
AFT were administered to treatment group subjects
before the third, fourth, and fifth rotating chair motion
sickness tests (6 hours total). Results showed that subjects
who received AFT had significantly greater motion
sickness tolerance (rode longer) than subjects performing
an alternative cognitive task or those performing no task.
Although the cognitive task group had slightly greater
mean tolerance than the no-task control group, the
difference was not statistically significant.
In another experiment, the objective was to determine if
an individual's initial susceptibility to motion sickness
was related to the ability to learn to control one's own
symptoms (Cowings and Toscano, 1982). Subjects were
assigned to groups based on their initial tolerance to
motion sickness in a rotating chair. Two AFT treatment
groups (highly and moderately susceptible to motion
sickness) were compared to two control groups who were
matched to the AFT groups for initial susceptibility, but
were given no treatment. Results showed that both AFT
treatment groups significantly improved their motion
sickness tolerance while neither control group improved
significantly. During the last two tests, after 6 hours of
AFT, the highly and moderately susceptible treatment
groups were no longer significantly different in their
motion sickness tolerance, while the high and moderate
control groups remained significantly different across all
tests.
The results of other studies (Cowings, 1990; Cowings,
Toscano, Sekiguchi, and Ishii, 1993) showed that (1) the
effects of AFT for symptom control are equal for both
men and women, (2) symptom control with AFT can be
retained for up to 2 years after training, and (3) the
primary component of the treatment effect in each of
these studies was attributed to learned control of
physiological responses. Subjects who increased their
tolerance to motion sickness consistently showed a
significant reduction in the magnitude of changes in their
autonomic responses after training.
Experiments in the literature (Reason and Brand, 1975)
and clinical experience show that habituation to a specific
nauseogenic situation does not transfer to new situations.
Repeated exposure apparently affects primarily the
sensory side (or "input" side) of the response system.
Autogcnic-Fccdback Training is aimed at controlling the
"output" side, i.e., the various symptoms or autonomic
manifestations of motion sickness. To the extent that such
control can bc learned, it is much more likely to transfer
to different situations that induce nausea, including the
unique condition of spaceflight.
An extensive examination of transfer of training was
made in another study which involved several different
types of stimuli that induce motion sickness (Cowings
and Toscano, 1993). Twenty-four men and women were
assigned to two equal groups, matched lot gender and
initial susceptibility to motion sickness in a rotating chair.
A second type of motion sickness test combined the
rotating chair with optokinetic stimulation in a rotating
drum that surrounded the chair. The subject's perception
of the combined stimulus was rotation in the opposite
direction of actual chair rotation. A final motion sickness
test was given to subjects using a vertical simulator that
produced slow up_lown motion.
The two groups of subjects, an AVI' treatment group and
a no-treatment control group were given the three types of
motion sickness inducing tests at the start of the study.
Treatment subjects were then given 6 hours of AFT over
5 days, while the control subject received no training.
Both groups of subjects were given their second exposure
to the three motion sickness tests at the end of the experi-
rnent. Results showed that subjects given AFT signifi-
cantly improved their tolerance to the different types
of motion sickness tests, whereas the c_,ntrol subjects
did not.
The U.S. Air Force had adopted a similar form of AFT to
treat crewmembers for whom other methods had proved
unsuccessful in combating persistent air sickness in high-
pcrformance military planes (Levy, Jones, and Carlson,
1981; Jones, Levy, et al., 1985). They have found that
such training transfers from the rotating chair on the
ground to the variety of maneuvers in military flight well
enough to rclurn air crew that otherwise would have been
permanently grounded, to active flying duty.
Research m Heart Rate Variability
Studies of heart rate during motion sickness have focused
exclusively on changes in mean heart rate or changes in
heart rate variance (Money, 1970; Graybiel and Lackner,
1980; Cowings, Suter, et al., 1986; Igarashi, Himi, et al.,
1987). For example, Igarishi, Himi, et al. (198'7) reported
that an increase in r-r interval variance correlated with
susceptibility to sensory sickness in adult squirrel
monkeys. These reports implicate the autonomic nervous
system in the etiology of motion sickness, but have
limited practical application to spaceflight for two
reasons. First, the use of terrestrial motion sickness as a
model for space motion sickness is of questionable
validity. Second, conventional analysis of heart rate
changes only on the basis of changes in mean or changes
in variance gives only a limited representation of the
complete dynamics. This type of analysis will not, for
example, detect the presence of oscillations and is of
limited use in characterizing the sudden changes in heart
rate dynamics that may occur during spaceflight
(Goldberger, Thornton, et al., 1987). A more complete
understanding of cardiovascular dynamics during
spaceflight and their relation to space sickness requires
analysis of beat-to-beat heart rate fluctuations using time
series and spectral analysis techniques (Sayers, 1973;
Kitney and Rompelman, 1980; Akselrod, Gordon, et al.,
1981; Kobayashi and Musha, 1982).
Several reports in the medical literature demonstrate the
usefulness of heart rate spectral analysis (Goldberger,
Goldwater, and Bhargava, 1986; Pangani, Lombardi,
et al., 1986; Jarisch, Ferguson, et al., 1987). Whereas
sinus rhythm in healthy individuals is characterized by
considerable beat-to-beat variability and a broad band-
width spectrum, a variety of disorders are associated with
increased heart rate periodicity, and sometimes distinct
oscillations can be seen (Goldberger, Findley, Blackburn,
and Mandell, 1984). Examples of pathologic heart rate
oscillations have been described in fetal distress
(Karinemi and Ammala, 1981) and in congestive heart
failure (Goldberger, Findley, Blackburn, and Mandell,
1984). Goldberger (Goldberger and Rigney, 1987)
described low-frequency oscillations in sinus rhythm
prior to the onset of potentially fatal ventricular
tachyarrhythmias (sudden death syndrome). The
mechanism of the low-frequency oscillations (usually
0.03 Hz) in these conditions is not known, but probably is
related to an instability in neuroautonomic control.
Another feature of note is that heart rate oscillations are
observed to start and stop abruptly, a feature that indicates
a nonlinear type of system (Goldberger, West, and
Bhargava, 1985). In a preliminary study, Goldberger
(Goldberger, Thornton, et al., 1987) reported on low-
frequency (<0.03 Hz) heart rate oscillations in two
astronauts. Prominent oscillations were observed for both
subjects during periods of severe space motion sickness
and were characterized by marked sensitivity to rotational
movement,malaise,andanorexia.Thefrequencyspec-
trumofonesubject,afterecoveryfromsicknesswas
reported,idnotcontaintheusuallow-frequencyoscilla-
tions.However,inanothersubject,prominentoscillations
wereno,tedintermittentlyintheapparentabsenceofovert
symptoms.
Respiratorysinusarrhythmia(RSA)isoneof many
oscillationswhicharemanifestedintheheartratepattern.
It is,however,oneofthefewphysiologicaloscillations
whichmaybedirectlylinkedtoaspecificphysiological
mechanism.ResearchbyKatonandJib(1975)suggested
thatmeasurementofRSAamplitudecouldbeusedasa
sensitiveindexofparasympatheticcontroloftheheart
(i.e.,cardiacvagaltone).Otherexperiments(McCabe,
Younge,Porges,andAckles,1984;DellingerandPorges,
1984),inwhichvagalactivitywasmanipulatedwith
pharmacologicaltreatments(atropineandpropranol)
andelectricalstimulation,havealsoshownthatRSA
magnitudeisasensitiveindexofvagaltone.
InanexperimentbyCowings,Suter,etal.(1986),it was
reportedthatamongseveralutonomicmeasuresheart
ratewasthebestpredictorfsymptomsof motion
sickness.Theseauthorsconcludedthatmotionsickness
wascharacterizedbysympathetica tivation.However,
thisconclusionwassomewhatpremature,becausenotall
measureswereexclusivelyindicesofthesympathetic
nervoussystem.Anincreaseofheartrateduringmotion
sicknesscouldbecompletelyorpartiallyexplainedby
vagalwithdrawal.Infact,ina laterstudy(Uijtdehaage,
Stern,andKoch,1992)onvection-inducedmotion
sickness,RSA,exclusivelyreflectingvagalchronotropic
control,wasfoundtobepredictiveofsymptomlevels.
Thatis,highlevelsofvagaltonewereinverselyrelatedto
motionsicknesscores.Furthermore,increasesincardiac
vagaltonewerepositivelyassociatedwithnormalgastric
activity(3cpm)andnegativelyassociatedwithdys-
rhythmicactivityof thestomach(tachyarrhythmia).
Tachyarrhythmiaisbelievedtobeaphysiologicalanarker
ofnauseaingeneralandmotionsicknessinparticular(Grashuis,vanderSchee,andGeldhof,1985;Koch,
Stern,Vasey,andDwyer,1990).Supportforthisfinding
ofarelationshipbetweenRSAandmotionsicknesswas
shownintheworkbyVybiral,Bryg,etal.(1990).These
researchersmeasuredRSAandheartratebeforeandafter
administrationfscopolamine,apotent(anticholinergic)
anti-motionsicknessdrug.A strongincreaseinvagaltone
andaheartratedecreasewereobservedcomparedwith
predruglevels.Theparadoxicalparasympathomimetic
actionofscopolaminewasattributedtocentralstimula-
tionofvagalmotorcenters,whichoverruledtheweaker
parasympatholyticactionin theperiphery.Thecombined
resultsofthisstudyanddatareportedbyUijtdehaage
(Uijtdehaage,Stern,andKoch,1992)suggestthata
generalstateofincreasedperipheralparasympathetic
activitycanalleviatemotionsicknessymptomsby
suppressing,inpart,itsgastricdysrhythmic
underpinnings.
Inlightoftheaboveresults,thestudiesbyCowings
(Cowings,Toscano,Sekiguchi,andIshii,1993;Cowings
andToscano,1993)demonstratethatheprimaryphysio-
logicaleffectofAFTinalleviatingmotionsickness
wasareductioni themagnitudeofautonomicresponse
changesobservedinsubjectsaftertraining.Theseauthors
alsospeculatethatageneralstateof increasedpara-
sympathetictone,seenwithAFTsubjects,canalleviate
motionsicknessymptoms.Furtherstudiesareneeded
thataddressthephysiologicalmechanismbywhichAFT
altersmotionsicknessusceptibility.
TheCurrentStudy
ThisstudyinvestigatedtheuseofAFTforalleviating
symptomsofSMSinastronauts,asanalternativetreat-
mcntopharmacologicalm nagement.Thehypothesesof
theexperimentwere(I) AFTadministeredbeforeflight
will reduceoreliminatethesymptomsofspacemotion
sickness;(2)datarecordedinspacewillobjectively
revealeffectsofearlyexposuretomicrogravity(when
comparedtoground-baseddata)onhumanphysiological
responsesandcanbeusedtoevaluatehecourseof
adaptationtothatenvironment;and(3)individual
susceptibilitytospacemotionsicknesscanbepredicted
onthebasisofeachcrewmembcr'sdemonstratedability
tolearncontrolofhisorherownphysiologicalresponses
duringpreflightAFT.
Thespecificobjectivesofthestudywere,first,to
determinetheeffectsofpreflightAFTonsusceptibilityto
motionsicknessandsymptomlevelsinducedbystressful
Coriolistimulationi arotatingchair.All subjectswere
givenabaselinemotionsicknesstestinarotatingchairto
measuretheirinitialtolerance(numberofrotations
achieved),andsymptomlevelstothisstimulus.Treat-
mentsubjectswereretcstedintherotatingchairatone
wcckintervalsafter2,4,and6hoursofAFTandchanges
inmotionsicknesstoleranceandsymptomlevelswere
comparedtotheirpretreatmentscores.Control subjects
were given only one exposure to the rotating chair motion
sickness test. Cowings, Billingham, and Toscano (1977)
showed that repeated motion sickness testing at I week
intervals in untreated subjects does not influence their
susceptibility. Second, to investigate changes in heart rate
variability, vagal tone, and coherence between heart rate
and respiration during motion sickness in a rotating chair
and a vertical motion stimulus. Although preliminary data
from space suggest that low-frequency heart rate
oscillations may provide a sensitive diagnostic marker of
motionsickness,it isnotknownwhetherterrestrial
motionsicknessi associatedwiththeseoscillationsand
if sowhethertheyoccuratthesamefrequenciescharac-
teristicofSMS.TheeffectsofAFI"onthesemeasure-
mentsduringmotionsicknesstestingwerealsoexamined.
Third,todetermineif AFTiseffectiveforpreventingor
alleviatingmotionsicknessymptomsduringactual
spaceflight.ToevaluateAFTtreatmenteffects,self-
reportedsymptomsofmotionsicknesswerecomparedfor
treatmentandcontrolsubjectsonmissiondays1,2,3,
and4.Andlast,toexaminechangesinphysiological
responsestospaceflight.Thesepsychophysiologicaldata
werethencomparedtoground-basedsimulationsof
specificmissiondays.Duringflight,continuousphysio-
logicalrecordingswcrecollectedfromsubjectsduring
wakefulperiodsonmissiondaysI, 2,3,and4.
Methods
Overview
This experiment represents part of a larger study that was
approved by NASA as a life sciences flight experiment to
be flown on several Space Shuttle missions and required
obtaining data on a total of sixteen subjects (eight
treatment and eight controls). This experiment was first
flown on the Space Shuttle in 1985, and during that
mission data were collected on four crewmembers (two
treatment and two controls). The experiment was reflown
on another Shuttle mission in 1992, in which two crew-
members served as subjects (one treatment and one
control). The current study included the six flight subjects
(three treatment and three controls) from two previous
Shuttle missions. The assignment of treatment and control
subjects was not random. Because mission training
schedules were different for each astronaut, only those
who were available to participate in 3 weeks of preflight
AFT served as treatment subjects.
Subjects
Thirteen people (four women and nine men) participated
in the preflight activities for this experiment. Ages ranged
from 32 to 59 years. Six of these subjects subsequently
flew in space, while six other subjects served as their
alternates and did not fly. One additional subject was an
active duty military pilot who received AFT in parallel
with the astronauts. This pilot was attempting to over-
come air sickness in the F- 18 tactical fighter aircraft.
There were three treatment and three control (four men
and two v,_men) flight subjects. All subjects were medi-
cally and otherwise qualified to serve as crewmembers on
scheduled Space Shuttle missions. Informed voluntary
consent was obtained and all procedures were approved
by NASA's human research review boards at Ames
Research Center, Johnson Spaceflight Center, and the
University of California at San Francisco.
Apparatus
Motion sickness stimuli- A Stille-Werner motor
powered rotating chair was used to induce the initial
symptoms of motion sickness. The chair was located
within a sound attenuated room which was temperature
controlled (70 + 2°F). Subjects were seated in the rotating
chair and the center of rotation was through their own
vertical axis (spine). Padded headrests were mounted on
the sides, front, and back of the chair, which allowed the
blind-folded subject to execute head movements in
randomized directions at 45 degree angles from the
upright position. Preamplifiers for physiological signals
were mounted on the rear of the chair and a belt-worn
physiological monitoring system (see Physiological
Measures) was secured around the waist of the subject.
The amplified signals were sent through slip rings in the
base of the chair to laboratory recorders.
Subjects were given a second motion sickness test using
the Vertical Acceleration and Roll Device (VARD) at
Ames Research Center. The VARD is a light-proof
enclosed cab which can achieve a maximum vertical
displacement of+6 feet (+1.829 m), without roll or pitch.
The frequency and gravity load are programmable.
Preamplifiers for physiological measures were mounted
in the cab. These signals were sent through a cable in the
rear wall of the cab to laboratory recorders. All physio-
logical data were recorded on two 8 channel strip chart
recorders and a 14 track FM analog tape recorder,
and were processed in real time and stored on a
Masscomp 6600 computer.
Symptom diagnostic scale- During each 5 minute
interval throughout the motion sickness tests, subjects
were asked to report their symptoms to the experimenter.
The symptoms were graded using a standardized
diagnostic scoring procedure (Graybiel, Wood, Miller,
and Cramer, 1968). Table 2 is an outline of the diagnostic
scale used. Frank vomiting (VMT) was indicated as either
present (I) or absent (no entry). The array of symptoms
included increased temperature (TMP), dizziness (DIZ),
headache (HAC), drowsiness (DRZ), sweating (SWT),
pallor (PAL), and salivation (SAL). The presence or
absence and/or strength of most symptoms were assessed
subjectively by the subject as mild "I," moderate "II," or
severe "III." Nausea was evaluated as epigastric aware-
ncss (EA) cpigastric discomfort (ED), and nausea (NSA).
_H ,,,
Malaise level Points
Table 2. Motion sickness diagnostic scale
VMT TMP DIZ ||AC DRZ SWT PAL SAL NSA ED EA
Pathognomic 16
Major 8
Minor 4
Minimal 2
AQS 1 I,II I,II I
IlI III lll IIl II,III
il lI 1I lI 1
I 1 I I
For example, a subject may report headache (1 point),
moderate drowsiness (4 points), and severe sweating
(8 points), summing to 13 points.
Motion sickness scores between I and 4 points repre-
sented mild malaise, scores between 5 and 7 represented
moderate malaise, scores of 8 or higher represent severe
malaise with 16 points scored for vomiting (i.e., frank
sickness).
Physiological measures- The Autogenic-Feedback
System-2 (AFS-2) is a portable belt-worn physiological
monitoring system (fig. I) developed by NASA to
support the flight experiment flown in 1992. An earlier
version of this system, the AFS- I, was used to support the
experiment flown in 1985 and redesigned to improve
signal quality and crew mobility. Physiological measures
recorded with both systems were identical. The AFS-2
includes a garment, transducers, signal conditioning
amplifiers, a digital wrist-worn feedback display, and a
cassette tape recorder. The wrist display provided
treatment subjects with continuous numeric feedback of
heart rate, respiration rate, blood volume pulse, skin
conductance, and skin temperature. Hardware mal-
function indicators and tirne were also provided to
subjects via display. The entire instrument is powered
by a self-contained battery pack.
The physiological measures recorded with the AFS-2
were:
Electrocardiography: Three pregelled Ag/AgC1
disposable electrodes were placed on the chest just below
the left and right clavicles (distally), and on the left
midclavicular line over the fburth intercostal space.
Respiration: A piezoelectric transducer was attached
to the garment with snaps over the chest to measure _he
respiratory waveforms.
Finger pulse volume: An infrared photo transistor
and detector was mounted in a ring positioned on the
volar surface of the small finger on the left hand for
measuring relative changes in peripheral vasomotor
activity.
Skin temperature: A solid state temperature
transducer was also mounted in the same ring for mea-
suring skin surface temperature at the same location.
Skin conductance level: Two pregelled Ag/AgC1
disposable electrodes were mounted on the volar surface
of the left wrist and spaced 1 inch apart to measure the
conductivity of the skin produced by moisture from the
sweat glands.
Additionally, the AFS-2 recorded head motions in the
X, Y, and Z planes from a triaxial accelerometer mounted
on a headband.
Other physiological measures recorded with standard
laboratory equipment included:
Electromyography: Three pregelled Ag/AgCI
disposable electrodes were attached to the forearm
extensor muscles of the arms and the gastrocnemius
muscles of the legs to measure the muscle activity at
these locations.
Skin conductance: An electrolyte paste (skin saline
concentration) was applied to two Ag/Ag CI electrodes
and these were attached to the tips of the right index and
middle fingers with velcro.
Finger pulse volume: A photoplethysmograph
transducer was attached with a finger clip to the little
finger of the right hand to measure relative changes in
peripheral vasomotor activity.
Skin temperature: A thermistor was taped to the
small finger on the right hand to measure the skin
temperature at this site.
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Figure I. The Autogenic-Feedback System-2 (AFS-2).
Procedures
Preflight- All subjects were initially given two baseline
motion sickness tests on separate days, one in the rotating
chair and the other in the vertical motion simulator. Each
subject also participated in two resting baselines given on
consecutive days, and one 12 hour mission simulation.
Additionally, treatment subjects were given twelve train-
ing sessions and three rotating chair mntion sickness tests
over 3 weeks.
On each day of motion sickness testing subjects were
given a brief orientation on the test procedures. They
were then seated in the rotating chair or vertical motion
simulator, and their physiological sensors were attached.
Following a 10 minute baseline condition (no rotation),
the chair was rotated to 6 rpm (0.628 rad/s) and main-
tained at this speed for 5 minutes. During the 5 minute
period of rotation, subjects were instructed by a tape
recorded voice to make head movements (front, back,
left, and right). The order of the head movements was
randomized and the duration of each movement was
I second. At the end of each 5 minute period the subject
held his head in the upright position for 30 seconds (while
rotation continued) and reported his symptoms to the
experimenter. The rotation continued at increasingly
higher speeds, incrementing by 2 rpm (0.209 rad/s) every
5 minutes, until the subject reached severe motion
sickness or was unwilling to continue or had reached a
maximum velocity of 30 rpm (3.142 rad/s). When the
rotating chair was finally stopped, another 10 minute
baseline period was taken.
During vertical motion tests, the frequency and gravity
load were held constant at 0.33 Hz, 0.35 g. Again,
subjects were instructed by the same tape recorded voice
to make head movements and report their symptoms
every 5 minutes throughout the test. Vertical motion tests
were terminated after 75 minutes or when the subjects
reached severe malaise or they were unwilling to con-
tinue. Pre- and posttest baseline periods (10 minutes)
without motion were also included in these tests.
Resting baselines of physiological responses were
recorded from subjects while they were seated in a chair
in a sound attenuated room and listened to tape recorded
music for 30 minutes. This procedure was repeated the
next day.
Flight subjects also participated in a mission simulation.
Physiological responses were recorded continuously for
I0
12 hours with the AFS-2 while subjects performed
procedures related to this experiment and other scheduled
flight experiments.
Treatment subjects were to be given 12 APT sessions
that were distributed over 3 weeks. Training sessions
(30 minutes each) were conducted in a stationary chair
within a sound-attenuated room over four consecutive
days each week. A rotating chair motion sickness test was
given on day 5 of each week. The purpose of these
motion sickness tests was to examine AFT effects on
changes in motion sickness tolerance, symptom levels,
and physiology.
Training sessions were divided into ten 3 minute trials in
which subjects were instructed to increase and decrease,
on alternate trials, their autonomic response levels. In an
earlier study (Cowings and Toscano, 1982) it was shown
that bidirectional training was more effective for symp-
tom control than training in only one direction. Physio-
logical feedback was displayed to subjects as a raw
analog waveform (e.g., respiration) on a CRT, a
numeric display, and/or an auditory tone. Autogenic
self-suggestion exercises were used by subjects to help
them produce response changes in the desired direction.
Training sessions were preceded and followed by
6 minutes of baseline.
Flight- Continuous physiological recordings were
collected with the AFS-2 during waking hours (approxi-
mately 12 hours) on the first four mission days from both
treatment and control subjects.
An I I item diagnostic log book (fig. 2) was used by the
subjects to report the type and severity of their symptoms
(Graybiel, Wood, Miller, and Cramer, 1968; Cowings,
Suter, et al., 1986). This diagnostic scale was identical to
that used in preflight motion sickness testing, except that
subjects were trained to self-report their own symptoms in
space.
Timelined symptom reporting was performed by subjects
immediately after awakening in the morning and before
retiring at night. If space motion sickness occurred at any
other time during the day, those symptoms were also
reported. Subjects also made written comments describing
their symptoms (e.g., if different from symptoms on
Earth) and evaluated the effects of AFT on symptom
control.
SUBJECT'S ID#
II II
PRE AFT POST AFT
TIME (GMT)
TIME SYMP
LINE CONT VMT TMP DIZ HAC
I I,I1 I,II I
SYMPTOMS OBSERVED
DRZ SWT PAL SAL NSA ED EA
I,II, I,II, I,II, I,II, I,II, I I
III III III III III
COMMENTS:
Figure 2. Illustration of the diagnostic log book.
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Treatment subjects also performed daily 15 minute AFT
sessions in which they practiced control of their physio-
logical responses using feedback from their wrist-worn
display. If space sickness symptoms occurred, the subject
attempted to alleviate the symptoms with AFT. These
symptom-contingent sessions were 30 minutes
in duration.
Posfflight- On the day of landing, each subject attended a
private 15 minute briefing with the experimenter, and
specific details pertaining to this experiment were noted.
Flight hardware, data tapes, and diagnostic log books
were removed from the Shuttle and returned to the
experimenter tot data processing. Two weeks later each
subject attended another private 2 hour meeting with the
experimenter to discuss his or her data and to help explain
unusual data anomalies possibly due to changes or delays
in conducting flight procedures.
Data analysis plan- Analyses of physiological data
included the heart rate and respiration measures obtained
during preflight motion sickness tests, during a mission
simulation, and during spaceflight. Other data analyses
included the motion sickness symptom scores collected
during the preflight motion sickness tests and self-reports
of symptoms during flight. Preflight motion sickness
tolerance, measured as the number of rotations, was also
analyzed to examine AFT effects on this variable.
Although recordings of other physiological measures
were obtained during this experiment, only analyses of
heart rate and respiration data are included here. The
other physiological variables and data obtained during
preflight training (AFT) will be discussed in a
future paper.
Analog electrocardiographic and respiration data were
digitized at 100 samples/s via a 12 bit A/D converter
using the Lab Workbench data acquisition program on a
Concurrent 6600 computer. The stored ECG and respira-
tion records for each subject were displayed on the
monitor in successive 8 minute screens and subjected to a
program for artifact removal and interpolation of missing
beats. Inter-beat intervals (r-to-r peaks) were computed
from the ECG records of all subjects using a custom peak
detection program. Heart period data were then converted
to a weighted heart rate (4 samples/s) to establish equal
time intervals, and the respiration data were subjected to a
smoothed average (4 samples/s). Before analysis the
entire heart rate and respiration series for each subject
was high-pass filtered (0.(X)5 Hz) and the mean was
centered to zero.
The hcart ate and respiration data from preflight motion
sickness tests were then divided into contiguous 5 minute
time blocks (epochs) that included (1) Two prerotation
baselines. (2) Five minutes at each rotational speed (e.g.,
6, 8, 10 rpm, etc.). Time of rotation was based on indi-
vidual tolerance to the stimulus; therefore, the number
of epochs of rotation for each subject varied. (3) Two
postrotation baselines. Spaceflight data, consisting of
approximately 12 hours on each day (mission days 1,
2, 3, and 4), were divided into contiguous 8.5 minute
time epochs.
A spectral analysis program (BMDPIT) on the PC was
used to analyze the heart rate and respiration data.
Applying a cosine window, the first and last 5 percent of
data in each epoch were tapered to zero to reduce arti-
factual end effects, and then Fourier transformed. Spectral
density estimates were formed from an average of
adjacent periodograms within a bandwidth of 0.015 Hz.
To quantify the power in different frequency bands, each
heart rate spectrum was divided into three bands: a low-
frequency band that encompasses the oscillations reported
by Goldberger (Goldberger, Thornton, et al., 1987) in a
preliminary study of space motion sickness (<0.05 Hz),
a mid-frequency band (>0.05, <0.1 Hz), and a high-
frequency band (>0.1, <0.4 Hz) that encompasses the
usual respiratory frequency. The power in each band was
calculated using the root-mean-square (rms) measure-
ment, and the rms value for the entire spectrum was also
computed. The rms spectral power in each band was
expressed in two ways: as an absolute value and also as a
percent of total power in the entire spectrum.
Two auxiliary analyses were performed (I) the weighted
coherence (Porges, Bohrer, et al., 1980) between heart
rate and respiration, and (2) estimates of cardiac vagal
tone (Porges, 1985) from the amplitude of respiratory
sinus arrythmia (RSA) as seen in heart rate data. Cross
spectral analyses (BMDPIT) were used to generate a
coherence function, a measure of covariation between
heart rate and respiration. Then a weighted coherence
(Cw) was derived by weighting the coherence function
across a band of frequencies (>0.1, <0.4 Hz) by the
spectral densities. Cw may provide a quantitative estimate
of stretch receptor influence on heart rate activity (Porges,
Bohrer, et al., 1980). Estimates of cardiac vagal tone were
derived by spectral analysis of heart rate epochs. First, a
third order moving polynomial window (10 seconds) was
applied to the heart rate series to remove aperiodic trends,
then the series was bandpass filtered (>0.1, <0.4 Hz) to
allow nominal respiratory frequencies to pass, and finally
the new heart rate series was subjected to spectral analysis
to obtain estimates of vagal tone.
Group comparisons of the physiological data were
performed on selected time epochs of the preflight motion
sickness tests, a mission simulation, and flight data using
multivariate analysis of variance (MANOVA) with
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repeatedmeasures(BMDP4V).TheGreenhouse-Giesser
methodwasusedtoreducethedegreesof freedomforthe
repeatedmeasuresanalyses,andatypeIerrorateof0.05
wasused.Forexample,acomparisonwasmadeofdata
obtainedduringamissionsimulationtodatacollectedin
spaceonthesamemissionday.Becauseenvironmental
conditionswerethesame(e.g.,workload,crewactivity
schedule),anydifferencesobservedinthesemeasures
couldbeattributedtotheeffectsofmicrogravity.Other
analyseswereperformedtodeterminepossiblediffer-
encesinphysiologicalresponsesovermissiondaysas
crewmembersadaptedtomicrogravity.
ThenonparametricFriedmananalysisofvariance
(ANOVA)forrelatedsampleswasusedtocompare
symptomscores(ordinaldata)acrossmotionsickness
testsfortreatmentgroupsubjects.It wasexpectedthat
theirscoresontests2,3,and4(2hoursoftraining
precededachtest)wouldbelowerthansymptomscores
ontest1(notraining).Preflightmotionsicknesstolerance
scoresoftreatmentsubjects,measuredasthenumberof
rotationsachieved,werecomparedacrossrotatingchair
testsusingarepeatedmeasuresANOVA.A Kruskal-
WallisANOVAforindependentsampleswasusedto
comparethesymptomscoresoftreatmentandcontrol
subjectsobtainedduringflightonfourmissiondays.
Results
Preflight Motion Sickness Tolerance Results
To examine AFT effects on changes in motion sickness
tolerance, the number of accumulative rotations for each
rotating chair test was computed for each subject and
used as the dependent measure for the analyses described
below. Figure 3 shows the distribution of motion sickness
tolerance scores for each treatment subject before AFT
(test 1) and alter AFT (test 4). Test I tolerance scores for
the three control group subjects (I.D.s 8, 12, and 13) are
also plotted on this graph. Asterisks are shown above the
bars for those subjects who flew in space. The center bar
graph represents treatment group (N = 10) means and
standard errors for tolerance scores on tests 1--4. Five of
these subjects repeated the training a year later because of
a delay in the mission. In the lower bar graph the means
and standard errors for this group (N = 5) are plotted for
tests 1-4 (first year) and tests 5-7 (second year).
The first analysis examined changes in motion sickness
tolerance of 10 treatment subjects during four rotating
chair motion sickness tests (test 1, no treatment; test 2,
after 2 hours of AFT; test 3, after 4 hours of AFT; and
test 4, after 6 hours of AFT). The ANOVA revealed a
significant effect for tests, F(I.48, 13.29) = 8.37,
p < 0.007, indicating that tolerance increased over tests.
Separate contrasts showed that motion sickness tolerance
significantly increased after 2 and 4 hours of AFT (test I
versus test 2, F(1,9) = 7.79, p < 0.02, and test 2 versus
test 3, F(1,9) = 8.72, p < 0.01), but did not significantly
increase after 6 hours of training (test 3 versus test 4). A
second analysis was performed using only the data of
subjects (N = 5) for whom the training was repeated.
Tolerance scores from test 1 (no treatment), test 4 (after
6 hours of AFT (first year)), and test 7 (after 6 hours of
AFT (second year)) were analyzed. Again, there was a
significant effect for tests, F(1.27, 5.08) = 7.04, p < 0.04,
suggesting that AFT increases tolerance to motion
sickness.
Specific contrasts show that during the first year after
6 hours of AFT, motion sickness tolerance did signifi-
cantly increase (test 1 versus test 4, F(I, 4) = 8.12,
p < 0.04), but during the second year after 6 hours of
AFT tolerance did not significantly increase (test I versus
test 7, F(I, 4) = 6.66, p < 0.06).
Preflight Symptom Score Results
Appendix A includes the graphs of each individual's
diagnostic scores plotted over 5 minute epochs of the
rotating chair motion sickness tests (figs. A- I-A- 13).
The number of symptom scores per test varied as
individual tolerance to the motion sickness stimulus
changed. Symptom scores were derived by totaling the
point values for each symptom reported during each test
epoch. The symptom scores of each subject were
averaged over the epochs of each test and were analyzed
to investigate Al=q" effects on changes in motion sickness
malaise. Table 3 lists the mean symptom scores of each
subject on four (N = 10) and seven (N = 5) rotating chair
tests. The first analysis compared the symptom scores of
10 treatment subjects across the four motion sickness
tests. The Friedman test statistic was significant,
X(3) = 12.36, p < 0.006, and specific comparisons
revealed that test 1 versus test 3 and test I versus test 4
were significant, Z(3) = 2.94, p < 0.05, and Z(3) = 3.12,
p < 0.05, respectively. Motion sickness discomfort was
significantly decreased following 4 and 6 hours of
training for this group. Two additional analyses were
conducted to compare the symptom scores of five treat-
ment subjects across four motion sickness tests in their
first and second year of training. Table 4 shows the mean
symptom scores of each subject on seven motion sickness
tests. No significant change in symptom scores was found
over the four tests for the first year, although the compari-
son of test I versus test 4 did approach significance.
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Figure 3. Individual and group changes in motion sickness tolerance before and after training.
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Table 3. Mean symptom scores for treatment subjects
across four rotating chair motion sickness tests (N = 10)
Subject Test 1 Test 2 Test 3 Test 4
I.D.
1 2.6 3.8 3.0 2.08
2 8.0 6.5 2.4 3.71
3 9.0 5.5 4.0 3.33
4 6.67 5.67 5.75 3.6
5 7.0 4.6 3.67 3.3
6 5.5 3.57 2.14 3.22
7 4.75 2.4 0.38 5.67
9a 5.33 2.66 3.0 3.16
10a 6.0 1.83 2.14 1.75
11a 10.1 1.33 4.0 4.5
aFlight treatment subjects.
During the second year, there was a significant change in
symptom scores over tests, X(3) = 7.8, p < 0.05, and only
the comparison of test 1 (no treatment) versus test 7 was
significant, Z(3) = 2.69, p < 0.05. Malaise was signifi-
cantly reduced for this group, but only after the training
was completed in their second year.
Preflight Physiological Results
Another set of analyses was conducted on the physio-
logical data collected during the preflight motion sickness
tests to explore (1) the time course of physiological
responses to motion sickness stimuli, and (2) the effects
of AFT on physiological responses to motion sickness.
Ten physiological measures were used as variates in a
repcated measures MANOVA. The variates were
(1) heart rate (HR), (2) respiration rate (RR), 3() vagal
tone (VT), (4) coherence of heart rate and respiration
(COHER), (5-7) root-mean-square values computed
from the spectral estimates of heart rate in the low-, mid-,
and high-frequency bands (RMSLOW, RMSMID,
RMSHIGH), and (8-10) the ratio of the power in each
heart rate frequency band to the total power in the
spectrum (RATIOLOW, RATIOMID, RATIOHIGH).
Five minute time epochs that were common to all subjects
during motion sickness tests were selected for analyses.
These epochs were two prerotation baselines, 6 RPM,
8 RPM, End (before chair rotation stopped), and two
postrotation baselines. Identical epochs were selected lor
the vertical motion test.
The first analysis examined the physiological responses
of 13 subjects (10 treatment, 3 controls) during their
initial exposure to the rotating chair. Figures 4 and 5
show the means (N = 13) for each of the physiological
measures plotted over time epochs of the first rotating
chair motion sickness test. A significant effect for epochs
was observed for heart rate, F(2.36, 28.33) = 12.38,
p < 0.0001 ; respiration rate, F(3.10, 37.26) = 3.84,
p < 0.02; vagal tone, F(2.89, 34.7) = 3.83, p < 0.02;
and coherence of heart rate and respiration,
F(3.58, 42.96) = 5.0, p < 0.003. Heart rate was low
in the prerotation baselines, increased abruptly and
remained high over rotation epochs, and decreased in
the postrotation baseline. Respiration rate was relatively
stable during the prerotation baselines and during
rotation, but decreased in the postrotation baselines.
Vagal tone was low in the initial prerotation baseline
and increased before rotation. A gradual decrease in
vagal tone was observed over rotation epochs and the
decrease continued in the postrotation baselines.
Coherence was stable in the prerotation baseline epochs,
decreased over epochs of rotation, and increased in the
final postrotation baseline.
Table 4. Mean symptom scores for treatment subjects across seven rotating chair motion sickness tests (N = 5)
First year Second year
I.D. Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7
1 2.6 3.8 3.0 2.08 4.2 1.28 0.31
2 8.0 6.5 2.4 3.71 3.33 7.0 3.66
3 9.0 5.5 4.0 3.33 7.0 2.67 4.0
4 6.67 5.67 5.75 3.6 3.0 3.71 3.63
9 5.33 2.66 3.0 3.16 3.86 4.16 3.0
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Figure 4. Group means of physiological responses to the first rotating chair motion sickness test (N = 13).
A second analysis examined changes in the physiological
responses of six subjects (four subjects were excluded
from the analysis because their data were incomplete) to
two types of motion sickness stimuli, a rotating chair and
a vertical motion simulator. A significant two-way
interaction (tests x epochs) was found for RMSMID,
F(3.66, 18.28) = 3.15, p < 0.04, and for RATIOMID,
F(2.78, 13.88) = 3.56, p < 0.04. During the rotating chair
test, heart rate variability in the mid-frequency band
showed a gradual increase from the prerotation baseline
to the end of rotation and then a decrease in the post-
rotation baseline. This trend was not as apparent during
the vertical motion test. In fact, RMSMID was initially
higher and appeared more stable during this test than
during the rotating chair stimulus. A similar effect was
observed for RATIOMID. Heart rate variability in the
mid-frequency band appeared to be more sensitive to the
rotating stimulus than to vertical motion.
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Figure 5. Group means of heart rate variability (expressed as rms power) and percent of total power in three frequency
bands during specific epochs of the first rotating chair motion sickness test (N = 13).
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A third analysis was conducted to investigate AFT effects
on physiological responses during motion sickness
stimulation in a rotating chair. Ten physiological
variables of treatment subjects (N = 10) were examined
before training (test 1) and after 6 hours of AFT (test 4).
Again, epochs were included as a factor in the analysis to
assess the time course of physiological responses to the
stimulus. The test × epochs interaction was significant
for COHER, F(3.49, 31.37) = 3.71, p < 0.01, and
RATIOMID, F(3.75, 33.77) = 2.61, p < 0.05. Only one
other physiological variable approached significance,
RATIOLOW, F(2.88, 25.94) = 2.74, p < 0.06. Visual
inspection of figures 6 and 7 reveals that coherence
between heart rate and respiration over epochs of the
motion sickness test was higher after training (test 4) than
before (test 1). Figure 7 shows that before AFT (test I)
percent power in the mid-frequency band of heart rate
variability gradually increases over epochs, and after AFT
(test 4) the ratio is initially higher and then decreases over
epochs. The inverse can be seen for percent power in the
low-frequency band. Before training (test I) the ratio is
initially higher and slightly decreases over the epochs, but
after training the ratio is initially lower and then increases
over epochs of the test.
Two final analyses of the physiological measures from
the preflight motion sickness tests were conducted using
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bands during specific epochs of rotating chair motion sickness tests before and after training (N = 10).
the data of treatment subjects (N = 5) who were given
AFT over 2 years. In the first analysis, l0 physiological
variables from test 1 (no treatment) and test 4 (6 hours of
AFT (first year)) were compared over the epochs of each
test. The tests x epochs interaction was not significant for
any of the physiological variables. Figure 8 shows the
group means for heart rate, respiration, vagal tone, and
coherence over specific epochs of motion sickness tests.
A second analysis compared the physiological measures
of test I (no treatment) and test 7 (after 6 hours of AFT
(second year)) for the same time epochs. A significant
tests × epochs interaction was found only for RMSMID,
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Figure 8. Group means of physiological responses to rotating chair motion sickness tests before and after training during
the first and second year (N = 5). First year = tests 1 and 4, second year = test 7.
F(2.49, 9.97) = 3.22, p < 0.05. Figure 9 shows that on test
I heart rate variability in the mid-frequency band sharply
increases over epochs until the end of rotation and then
decreases during the postrotation baseline. During test 7,
after 6 hours of AFT, the power in this frequency band is
initially higher in the prerotation baseline and then
decreases over epochs until the postrotation baseline.
Flight Symptom Score Results
Table 5 lists the type and frequency of symptoms reported
by each subject during 4 days of spaceflight. The three
treatment subjects who were given preflight AFT for
control of their motion sickness symptoms did not take
antimotion sickness medications during the flight.
However, ,he two of the three control subjects, who were
given no preflight treatment, took antimotion sickness
medications for symptoms experienced during flight.
Note that this was the second spaceflight for subject 13.
Table 6 represents the symptom score totals of each
subject on each mission day. The scores were derived by
summing the point values for the individual symptoms
reported on each day. These data were analyzed to
examine group effects and changes in motion sickness
malaise over days. No significant group difference was
found. But, there was a significant difference over the
4 days (N = 6), indicated by the Friedman test statistic,
X(3) = 13.55, p < 0.003. Comparisons showed that day I
versus day 3 and day I versus day 4 were significant,
Z(3) = 2.80, p < 0.05, and Z(3) = 3.24, p < 0.05,
respectively. Motion sickness malaise was significantly
reduced by mission day 3.
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Table 5. Motion sickness symptoms reported over mission days
,,,J i
I.D Day I Day 2 Day 3 Day 4 Medication
Treatment group
9 Vomiting Vomiting Mild nausea Gastric Ducolax
(5 times) (I time) awareness
Mild Mild Mild
drowsiness drowsiness drowsiness
Mild salivation Moderate
nausea
Moderate
nausea
10 Mild nausea Headache None None None
Headache
Dizziness
II Moderate Vomiting None Facial pallor None
nausea (1 time)
Headache Mild nausea
Control group
None None None Restoril8 Moderate
nausea
Headache
12 Vomiting
(6 times)
Severe nausea
Profuse
sweating
Hyper
salivation
13a Vomiting
(2 times)
Mild
drowsiness
aSecond spaceflight.
Gastric Gastric None Compazine
discomfort awareness
Moderate Valium
nausea
Moderate Gastric None Reglan
nausea discomfort
Increased Valium
warmth
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Table 6. Symptom score totals for each subject over
mission days
I.D. Day I Day 2 Day 3 Day 4
Treatment group
9 28 26 6 I
10 6 I 0 0
11 9 20 0 2
Control group
8 9 0 0 0
12 40 10 1 0
13 26 8 3 0
Flight Physiological Results
Physiological data of the six flight subjects were analyzed
to examine (1) the effects of early adaptation to micro-
gravity (the first 4 days in space), (2) physiological
responses on day 2 in space compared to a ground-based
simulation of the same mission day, and (3) physiological
differences between treatment and control subjects over
mission days. Appendix B includes the graphs of each
individual's physiological data during spaceflight. The
data are plotted as contiguous 8.5 minute epochs over
each mission day. Missing data are indicated on the
graphs. The respiration data of four subjects could not be
processed because of poor signal quality. Group means
for each physiological measure, excluding RR and
COHER, were computed from the 8.5 minute epochs of
each flight day and a ground-based mission simulation.
Figures 10-13 represent the physiological means of all
subjects (N = 6), treatment subjects (N = 3), and control
subjects (N = 3) plotted over flight days (left bar graph)
and means comparing mission day 2 to a ground
simulation of the same flight day (right bar graph).
Standard errors are also plotted on the graphs. The first
analysis examined differences in the physiological
responses of treatment and control subjects over the
4 days of flight. No group differences over days were
observed; however, the mid-frequency band for heart rate
variability approached significance, F(2, 7.99) = 3.33,
p < 0.06. The treatment group showed a gradual increase
over days in the mid-band frequency for heart rate
variability, while this response for the control group was
the inverse. A significant day's effect was found only for
heart rate, F(2.77, 11.07) = 7.88, p < 0.004. Comparisons
of day I with each of the other flight days were all
significant, (day 1 versus day 2), F(I, 4) = 14.69,
p < 0.01; (day 1 versus day 3), F(I, 4) = 14.21,
p < 0.01; and (day I versus day 4), F(I, 4) = 17.69,
p < 0.01. Heart rate is initially high on the first day of
flight, significantly decreases by the second day, and
remains low over days 3 and 4.
The final analysis compared the physiological responses
of treatment and control subjects on day 2 of flight with
their data collected during a ground simulation of the
same mission day. Results of the MANOVA indicated a
significant day's effect (flight versus simulation) for HR,
F(1,4) = 90.08, p < 0.007; RATIOLOW, F(I, 4) = 8.39,
p < 0.04; RATIOHIGH, F(1, 4) = 7.90, p < 0.04. Heart
rate and percent power in the low-frequency band for
heart rate variability were both significantly lower in
space than on Earth. Percent power in the high-frequency
band for heart rate variability, which primarily reflects
respiratory sinus arrhythmia, was higher in space
than during the ground simulation. A significant
group's x day's effect was observed for heart rate only,
F(1,4) = 13.73, p < 0.02. The heart rate responses of both
groups were comparable in space, but during the ground
simulation heart rate was significantly higher for
treatment subjects (86 bpm) than controls (75 bpm).
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Discussion
The results of this experiment are in agreement with
previous studies (Cowings, 1990) demonstrating that AFI'
significantly increases tolerance to rotating chair motion
sickness tests. Further, it was shown that this increased
tolerance was associated with changes in specific
physiological responses and reports of reduced malaise.
However, subjects in this study varied widely in their
ability to learn control of motion sickness symptoms
as can be seen in the individual symptom reports
(appendix A). A possible explanation for this variability
in performance was the different AFT schedules used for
some subjects. Four treatment subjects (two flight and
two alternates) were given rotating chair tests over
intervals ranging between 30 and 300 days. Because of
delays in the mission launch date, mission management
rescheduled these subjects for AFT over a
17 month period.
For the other treatment subjects, we succeeded in
maintaining an AFT schedule more closely aligned to that
used in laboratory studies, which produced the most
effective learning of symptom control (Cowings, 1990).
These subjects received twelve 30 minute sessions
(6 hours total), administered in blocks of four consecutive
days over 3 weeks. Rotating chair motion sickness tests
were separated by 7 day intervals. In both cases, AFT was
initiated approximately 1 year prior to the scheduled
launch date. When delays in the launch date for this
mission were extended 1 year, these subjects received
an additional 6 hours of AFT. Despite the scheduling
changes for some of the astronauts participating in
preflight AFT, the results indicated that the training
method was an effective treatment for ground-based
motion sickness. It was concluded that the latter schedule
with AFT sessions on consecutive days produced better
learning.
The primary hypothesis of this research was that preflight
AFT would reduce or eliminate the symptoms of space
motion sickness. Previous research (Cowings, 1990)
showed that the AFT treatment effect transfers from
motion sickness stimulation in a rotating chair to vertical
up and down motion and to a combination of optokinetic
stimulation with rotation in a chair. AFT apparently
operates on the final common path in the development of
motion sickness symptoms. The demonstrated ability to
transfer training effects to a variety of Earth-based motion
environments led us to hypothesize that AFT would
transfer to space as well.
The flight results showed that two of the three control
subjects experienced multiple vomiting episodes on the
first mission day, while one control subject experienced
only moderate malaise. All control subjects took
medication for symptom suppression and/or sedation. Of
the three treatment subjects, one experienced only mild
discomtort, one experienced moderate discomfort (one
w_miting episcgle on mission day 2), and one experienced
severe motion sickness on the first day. The latter subject
took a laxative on mission day 4 for symptoms unrelated
to motion sickness. None of the otber treatment subjects
took any medication throughout the flight. These data
suggest that AFT may be an effective treatment for space
motion sickness; however, this cannot be demonstrated
conclusively with the small number of subjects described
in this paper.
Physiological data obtained in space clearly demonstrate
changes over days as subjects adapted to that environ-
ment. Analyses of all six crewmembers showed a
significant decrease in heart rate over days. Vagal'tone
increased whereas low-frequency heart rate oscillations
decreased during spaceflight, although these trends were
not significant. However, review of the individual
physiological data obtained during spaceflight
(appendix B) shows that for any given crewmember,
within-subject changes in physiological responses across
days in space are associated with reports of reduced
malaise, i.e., adaptation to microgravity. For example,
subject 8, who was least affected by space motion
sickness of all the flight subjects, showed an increase in
vagal tone during the mission, and also had the highest
initial vagal tone on day 1. Further, coherence between
heart rate and respiration for this subject also increased
over flight days.
In contrast, subject 9, who was highly susceptible to
motion sickness, showed lower vagal tone when
symptoms were severe on early mission days and a
significant increase in vagal tone on those days when
symptoms were mild. Heart rate and respiration
coherence also followed the same pattern of change for
this individual. Further, an examination of heart rate
variability for this subject revealed dominant low-
frequency oscillations on the first day in space when
severe motion sickness was reported. However, these
dominant low-frequency oscillations were not as apparent
for other subjects for whom motion sickness was severe
and were also seen later in the mission when subjects
were asymptomatic.
The observations of increased vagal tone and higher
coherence between heart rate and respiration across
mission days suggest that cardiorespiratory regulatory
mechanisms may play a significant role in adaptation to
spaceflight. Although the basic anatomy for cardio-
respiratory coupling exists and has been demonstrated
under different conditions on Earth (Katona, Poitras,
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Barnett,andTerry,1970;DellingerandPorges,1984),
thefindingsofthecurrentstudyprovidenewinformation
forfurtherexaminationsofthedynamicbehaviorfthese
twosystemsasanindexof stress.Theresultsmayalso
haveimplicationsfordevelopingandtestingantimotion
sicknessmedicationsandfortheoptimizationofnon-
pharmacologicmodesoftherapy(e.g.,AFT)formotion
sickness.Forexample,simplypacingbreathingatoptimal
ratesmayentrainheartrateinawaythatbothsystemsare
sufficientlycoupled,whichmaythenprovidesubstantial
relieffromsymptoms.Anotherapproachmightinclude
trainingindividualstomodifyspecificpatternsofheart
ratevariance.Inparticular,t ainingpeopletoincreasethe
amplitudeorqualityofrespiratorysinusarrhythmia(RSA),whichcorrelateswithvagaltone(Porges,1985),
mayhelptopreventsymptomonset.
Comparisonsofflighttoground-basedimulationdata
revealedmarkedifferencesbetweenphysiological
responsesonEarthandinspace.Forallcrewmembers,
regardlessofgrouporsymptomlevelinspace,heartrate
variabilityinthelow-frequencyband(0.005to0.05Hz)
wasgreatlyreducedinspace,beingnearlyhalfthenormal
magnitude.Significantdifferenceswerealsofoundfor
heartrate(lowerinspace)andforheartratevariabilityin
thehigh-frequencyband(0.! to0.4Hz).Thelatter
measure,whichreflectsRSA,washigherinspacethan
onEarth.
Physiologicalresultsoflaboratorymotiontestshowed
thatheartrate,respirationrate,vagaltone,andcoherence
betweenheartrateandrespirationdochangeduringthe
initialexposuretomotionsicknesstimulation.These
findings are in general agreement with other reports
(Cowings, Suter, et al., 1986; Crampton, 1955) which
showed increases in heart rate and respiration rate to a
rotating chair stimulus, and decreases in vagal tone to a
rotating optokinetic drum (Uijtdehaage, Stern, and Koch,
1992). In the latter study it was also shown that initially
high levels of vagal tone were inversely related to malaise
scores and were predictive of motion sickness. The large
increases in heart rate during motion sickness observed in
the present study may partially be explained by vagal
withdrawal.
The comparison of physiological responses to a rotating
chair and a vertical motion stimulus showed that heart
rate variability in the mid-frequency band (0.05 to 0.1 Hz)
increased during motion sickness in the chair only. This
frequency band reflects changes in blood pressure control
mechanisms which typically appear as 8 to 10 second
cycles in the heart rate spectrum. Although blood pressure
recordings were not taken in this study, such information
would be useful to help explain the changes seen in heart
rate variability.
The effects of AFT on physiological responses during
rotating chair motion sickness tests showed that
coherence between heart rate and respiration was higher
after training than before. Heart rate variability in the
low-frequency band was initially reduced following AFT,
while the inverse was seen for the mid-frequency band.
Further, these effects were related to increases in motion
sickness tolerance and decreases in malaise. The paced
breathing given with AFT may partially explain the
changes in the pattern of heart rate variance. However, the
data also suggest that AFT indirectly modulates changes
in blood pressure, as was seen in the pattern for heart rate
variability.
Finally, it was concluded that ambulatory physiological
monitoring is an appropriate way of studying individual
differences in adaptation to spaceflight and the time
course of this adaptation. And, by examining the physio-
logical profiles of treatment subjects during preflight
motion sickness tests it was possible to accurately predict
which of the flight treatment subjects would be most
resistant and least resistant to symptoms in space. Treat-
ment subjects who were most resistant to space motion
sickness showed reduced autonomic variability during
preflight motion sickness testing, which strongly sug-
gested that they had learned better autonomic control.
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Appendix A
Individual Preflight Symptom Scores and Physiological Data
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Note: Tests 1-4 were at 1 week intervals. Test 5 was administered approximately 1 year later with tests 5-7, also at
1 week intervals.
FigureA- 1, Reports of motionsicknessmalaise across testswsubject I.
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Note: Tests I--4 were at I week intervals. Test 5 was administered approximately I year later with tests 5-7, also at
1 week intervals.
Figure A-2. Reports of motion sickness malaise across tests--subject 2.
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Note: Tests 1-4 were at I week intervals. Test 5 was administered approximately I year later with tests 5-7, also at
1 week intervals.
Figure A-3. Reports of motion sickness malaise across tests--subject 3.
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Note: Tests 1-4 were at I week intervals. Test 5 was administered approximately 1 year later with tests 5-7, also at
I week intervals.
Figure A-4. Reports of motion sickness malaise across tests--subject 4.
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Note: Tests were conducted at weekly intervals.
Figure A-5. Reports of motion sickness malaise across tests--subject 5.
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Note: Number of days between tests I and 2 = 234; 2 and 3 = 74; 3 and 4 = 54.
Figure A-6. Reports of motion sickness malaise across tests--subject 6.
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N_Te: Number of days between tests 1 and 2 = 201; 2 and 3 = 102; 3 and 4 = 57.
Figure A-7. Reports of motion sickness malaise across testsmsubject 7.
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Figure A-8. Reports of malaise during initial motionsicknesstestmsubject8.
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Note: Tests 1-4 were at 1 week intervals. Test 5 was administered approximately 1 year later with tests 5-7, also at
1 week intervals.
Figure A-9. Reports of motionsicknessmalaise across tests--subject 9.
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Figure A- 10. Reports of motion sickness malaise across tests--subject 10.
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Figure A- 11. Reports of motion sickness malaise across tests--subject 11.
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Figure A- 12. Reports of malaise during initial motion sickness test--subject 12.
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Figure A- 13. Reports of malaise during initial motion sickness test--subject 13.
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Figure A- 14(a). Heart rate and respiration rate acrossmotionsicknesstests(year 1)--subject 1.
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Figure A-14(b). Heart rate and respiration rate across motion sickness tests (year 2)--subject 1.
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Figure A-15(a). I-tedr_ _ate and r¢sp#ation mtF, across motion stckness tests (year l _--subjeci Z.
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Figure A-15(b). Heart rate and respiration rate across motion sickness tests (year 2)msubject 2.
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Figure A- 16(b). Heart rate and respiration rate across motion sickness tests (year 2)--subject 3.
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Figure A- ! 7(a). Hemt rate and _'es#,rauon ,'ale ac;ess me:riot, sickness tests (year 1)--subject 4.
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Figure A- 17(b). Heart rate and respiration rate across motion sickness tests (year 2)wsubject 4.
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Figure A-19. Heart rate and respiration rate changes across motion sickness tests--subject 6.
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Figure A-20. Heart rate and respiration rate changes across motion sickness tests--subject Z
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Figure A-21. Heart rate and respiration rate during initial motion sickness tests--subject 8.
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Figure A-22(a). Heart rate and respiration rate across motion sickness tests (year 1)--subject 9.
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Figure A-22(b). Heart rate and respiration rate across motion sickness tests (year 2)--subject 9.
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Figure A-23. Heart rate and respiration rate changes across motion sickness tests--subject 10.
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Figure A-24. Heart rate and respiration rate changes across motion sickness testsmsubject 11.
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Figure A-25. Heart rate and respiration rate during initial motion sickness testnsubject 12.
6O
Heart Rate
53
r-
om
¢_
q)
a.
(n
m
52
51
50 I I
baseline 6 8
I I
10 baseline
Respiration Rate
G)
.c_
:t
In
G)
a.
(n
.¢:
4-o
t_
4)
im
m
20
18
16
14
12
10
8 I I
baseline
i
6 8
Revolutions Per Minute
1 0 baseline
Figure A-26. Heart rate and respiration rate during initial motion sickness test--subject 13.
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FigureA-27. Changesincoherencebetweenheartrate and respiration acrosstests--subject 1.
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FigureA-28. Changes in coherence between heart rateand respirationacrosstestsmsubject2.
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FigureA-29. Changesin coherencebetween heart rateand respirationacrosstests--subject3.
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Figure A-30. Changes in coherence between heart rate and respiration across testsmsubject 4.
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Figure A-31. Changesin coherence between heart rate and respirationacrosstests--subject5.
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Figure A-32. Changes in coherence between heart rate and respiration across tests--subject6.
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Figure A-33. Changes in coherence between heart rate and respiration acrosstests--subject 7.
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Figure A-34. Coherence between heart rate and respiration rate during two baseline motion sicknesstests--subject8.
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Figure A-35. Changesin coherence between heart rate and respiration acrosstests--subject 9.
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Figure A-36. Changes incoherence between heart rate andrespirationacross tests---subject 10.
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Note: Number of days between tests 1 and 2 = 173; 2 and 3 = 125; 3 and 4 = 31.
Figure A-37. Changes in coherence between heart rate and respiration acrosstests--subject 11.
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Figure A-38. Coherence between heart rate and respiration during baseline motion sickness test--subject 12.
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Figure A-39. Coherence between heart rate and respiration during baseline motion sickness test--subject 13.
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FigureA-40. Changesin estimateof vega  toneacrossmotionsicknesstestsmsubject1.
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Note: Tests I-4 were at I week intervals. Test 5 was administered approximately 1 year later with tests 5-7, also at
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FigureA-41. Changesin estimateof vaga/toneacrossmotionsicknesstests--subject2.
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Figure A-42. Changes in estimateof vagal tone acrossmotion sicknesstests--subject 3.
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FigureA-43. Changesin estimateof vagaltoneacrossmotionsicknesstests--subject4.
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Figure A.44. Changesin estimate of vagal toneacrossmotionsicknesstests--subject 5.
>
,J
U)
12
10
8
• test 1 []test 2 •test 3 []test 4
6
4
2
0
baseline 6 8 10 12 14 16 18 20 22 baseline
Revolutions Per Minute
Note: Number of days between tests 1 and 2 = 234; 2 and 3 = 74; 3 and 4 = 54.
Figure A-45. Changesin estimateof vagal tone acrossmotion sicknesstests--subject6.
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Note: Number of days between tests 1 and 2 = 201; 2 and 3 = 102; 3 and 4 = 57.
FigureA.46. Changesin estimateof vagaltoneacrossmotionsicknesstests-subject 7.
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FigureA-47. Changes inestimateof vagaltoneduringtwobaselinemotionsicknesstests--subject8.
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Note: Tests 1-4 were at 1 week intervals. Test 5 was administered approximately I year later with tests 5-7, also at
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FigureA-48. Changes in estimateof vagal tone across motion sicknesstestsusubject 9.
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Note: Number of days between tests I and 2 = 189; 2 and 3 = 105; 3 and 4 = 34.
Figure A-49. Changes in estimate of vagal tone across motion sickness tests--subject 10.
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Note: Number of days between tests I and 2 = 173; 2 and 3 = 125; 3 and 4 = 31.
Figure A-50. Changes in estimate of vagal tone across motion sickness testsmsubject 11.
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FigureA-51. Estimateof vagaltonedurfngbaselinemotionsicknesstest--subject 12.
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FigureA-52. Estimateof vagal tone during baseline motion sicknesstest--subject 13.
?9
40..
30"
_20.
g
E10-
lb.
0
Test
[]high []mid []low
40 - • Test 2
30-.
' J,,AElO-
o - ;-_l:'l]';-rl,,,, ,,, , :jllr_,
0
Test 3
40 -- Test 4
30-I,,|
0=2o_
,.==10]
0
baseline 6 8 10 12 14 16 18 20 22 24 26 28 30 baseline
Revolutions Per Minute
Note: Tests 1-4 were at I week intervals. High = 0 to 0.05 Hz, mid = 0.05 to 0.1 Hz, low = 0.1 to 0.4 Hz.
Figure A-53(a). Heart rate variabilityacrossmotionsicknesstests(year 1)--subject 1.
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Figure A-53(b). Heart rate variability across motion sickness tests (year 2)--subject 1.
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Figure A-54(a). Heart rate variability across motion sickness tests (year 1)--subject 2.
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Figure A-54(b). Heart rate variability across motion sickness tests (year 2)--subject 2.
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Figure A-55(a). Heart rate variability across motion sickness tests (year 1)--subject 3.
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Figure A-55(b). Heart rate variability across motion sickness tests (year 2)--subject 3.
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Figure A-56(a). Heart rate variability across motion sickness tests (year 1)--subject 4.
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Figure A-56(b). Heart rate variability across motion sickness tests (year 2)--subject 4.
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Figure A-57. Heart rate variability across motion sickness tests--subject 5.
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Figure A-58. Heart rate variability across motion sickness tests--subject 6.
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Figure A-59. Heart rate variability across motion sickness tests--subject 7.
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Figure A-60. Heart rate variability during initial motion sickness test--subject 8.
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Figure A-61(a). Changes in heart rate variability across motion sickness tests (year 1)--subject 9.
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Figure A-61(b). Changes in heart rate variability across motion sickness tests (year 2)--subject 9.
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Figure A-62. Changes in heart rate variability across motion sickness tests--subject 10.
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Figure A-63. Changes in heart rate variability across motion sickness tests--subject 1 I.
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FigureA-64. Heartrate variabilityduringinitialmotionsicknesstest--subject 12.
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Figure A-65. Heart rate variability duringinitialmotion sicknesstest--subject 13.
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Appendix B
Individual Physiological Data During Spaceflight
and in Earth-Based Mission Simulations
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Figure B- I. Heart rate data of two crewmembers: launch day.
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Figure B-2. Heart rate and respiration rate changes during early adaptationto microgravity--subject8.
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Figure B-3. Heart rate and respiration rate in space vs. Earth-based simulations--subject 8.
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Figure B-4. Heart rate and respiration rate changes during ear/y adaptation to microgravity--subject 9.
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Figure B-5. Heart rate and respiration rate in space vs. Earth-based simulations--subject 9.
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Figure B-6. Heart rate changes during early adaptation to microgravity--subject 10.
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Figure B-8. Heart rate changes during early adaptation to microgravity--subject 11.
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Figure B-9. Heart rate in space vs. Earth-based simulations--subject 11.
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Figure B-10. Heart rate changes during early adaptation to microgravity--subject 12.
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Figure B- 11. Heart rate in space vs. Earth-based simulations--subject 12.
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Figure B-13. Heart rate in space vs. Earth-basedsimulations--subject 13.
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Figure B-14. Coherence between heart rate and respiralion during early adaptation to microgravity--subject 8.
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Figure B- 16. Coherence between heart rate and respiration during early adaptation to microgravity--subject 9.
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Figure B- 17. Coherence between heart rate and respiration in space vs. Earth-based simulationmsubject 9.
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FigureB-18. Estimateof vagal tonein space--subject8.
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FigureB-19. Estimateof vagaltoneinspace vs. Earth-basedsimulationsusubject8.
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Figure B-20. Estimate of vagal tone in space--subject 9.
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Figure B-22. Estimate of vagal tone in space--subject 10.
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Figure B-23. Estimate of vagal tone in space vs. Earth-based simulations--subject 10.
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Figure B-24. Estimate of vagal tone in space--subject 1I.
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Figure B-25. Estimate of vagal tone in space vs. Earth-basedsimulations--subject 11.
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Figure B-27. Estimateof vagaltone in space vs. Earth-basedsimulations--subject12.
1st Sim
Day 2
114
>_J
u)
1 11 21 31 41 51 61 71 81 91
epochs
Figure B-28. _mate of vagal tonem space---su_t 13.
Day 4
Day 3
Day 2
Day 1
>
.,J
25
20
15
10
5
0
1 11 21 31 41 51 61 71 81 91
epochs
Figure B-29. Estimate of vagal tone in space vs. Earth-basedsimulationsmsubject13.
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Figure B-31. Heart rate variability in space vs. Earth-based simulations--subject 8.
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FigureB-33. Heart rate variability in space vs. Earth-based simulations--subject9.
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Figure B-35. Heart rate variability in space vs. Earth-based simulations--subject 10.
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Figure B-37. Heart rate variability in space vs. Earth-based simulations--subject 11.
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Figure B-39. Heart rate variability in space vs. Earth-based simulations--subject 12.
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Figure B-41. Heart rate variability in space vs. Earth-based simulations--subject 13.
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Appendix C
Subject Consent Form

NASA HUMAN RESEARCH
MINIMAL RISK
INFORMED CONSENT FORM
o I, the undersigned, do voluntarily give my informed consent for my participation as a
test subject to the following tes4 experiment, or other evaluative procedure.
NAME OF EXPERIMENT:
TRAINING TOUR NUMBER:
FLIGHT TO WHICH ASSIGNED:
NAME OF DESIGNATED PRINCIPAL INVESTIGATOR:
NAME OF RESPONSIBLE NASA PROJECT SCIENTIST:
I understand that:
(a) This procedure is part of an experiment approved by NASA.
(b) I am performing these duties as part of my employment, with
(c) This procedure has been reviewed and approved by the JSC Human Research Policy
and Procedures Committee (HRPPC) and determined that the procedure involves no
more than minimal risk to the subject.
(d) "Minimal risk" means that the harm or discomfort anticipated in the proposed research
is not greater, considering probability and magnitude, than those encountered in the
daily lives of healthy individuals, including the recognized risks inherent in a chosen
occupation.
(e) I am medically qualified to participate in the procedure.
(0 I may withdraw from the procedure at any time unless, as recommended by the
Principal Investigator, or his/her designee, the withdrawal is dangerous or impossible.
(g) In the event of physical injury resulting from the procedure and calling for immediate
action or attention that NASA will provide, or cause to be provided, the necessary
treatment. I also understand that NASA will pay for any claims of injury, loss of life or
property damage to the extent required by the Federal Employees' Compensation Act or
the Federal Tort Claims Act. My agreement to parficlpate shall not be construed as a
release of NASA or any third party from any future liability which may arise from, or in
connection with, the above procedures.
(i) My identity will remain confidential, and no raw medical data or information will be
released to any group or individual without my prior written consent. This includes
NASA and its representatives (eg., NASA flight surgeons, etc.). I will have an
opportunity to review the mission report before its release. Under no circumstances
will data release cause compromise of my identity confidentiality without my prior
written consent.
PAGul[ LANK NOT FII.ME_
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2. I, the undersigned,thePrincipalinvestigatorof theexperimentdesignatedabove,certif3,
that:
(a) I haveaccuratelydescribedtheprocedureto thetestsubject.
(b) The test set-upinvolvesminimal risk to the test subject. All equipmentusedhasbeen
inspectedandcertified for safeandproperoperation.
(c) The test subject is medically qualified to participate.
(d) The test protocol has not been changed from that approved by the JSC Human Research
Policy and Procedures Committee (HRPPC).
APPROVED:
Test Subject Date
Principal Investigator Date
Project Scientist Date
This consent form is valid for a 60-day period from the date of signature by the subject and the
Principal Investigator (which dates would be identical). A signed, dated copy of the form
should be forwarded to the JSC Human Research Policy and Procedures Committee, Mail Code
SA, Lyndon B. Johnson Space Center, Houston, Texas 77058.
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